Tim Kong

926 citations

24 papers · 357 indexed · h-index 10

Impact in

Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Sensory Systems top 10%
- Ion Channels and Receptors

Papers in

Genetics 16
- Myeloproliferative Neoplasms: Diagnosis and Treatment 14
- Chronic Lymphocytic Leukemia Research 3
Hematology 13
- Acute Myeloid Leukemia Research 12

Co-authors: Stephen T. Oh Sidong Huang Xianbing Zhu Marie‐Christine Guiot Yibo Xue Morag Park Angelo B. A. Laranjeira Geneviève Morin
Journals: Blood (6 papers)Blood Advances (2 papers)Experimental Hematology (2 papers)Molecular Cancer Therapeutics (1 paper)Cancer Research (1 paper)
Partner nations: United States Canada United Kingdom

In The Last Decade

Tim Kong

24 papers receiving 352 citations

Peers

Countries citing papers authored by Tim Kong

Since Specialization

Citations

This map shows the geographic impact of Tim Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Kong more than expected).

Fields of papers citing papers by Tim Kong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Kong. The network helps show where Tim Kong may publish in the future.

Co-authors

The 25 scholars most cited alongside Tim Kong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim Kong Line = papers co-authored together Tim Kong links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	RSK1 dependency in FLT3-ITD acute myeloid leukemia Blood Cancer Journal ·Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, Pil J. Yoo, Lebedeva Lyudmila, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh	2024	2
2	A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis Therapeutic Advances in Hematology ·Tim Kong, Kristen Haynes, Eduardo Santiago Flores Sucuzhañay, Tsuneo IWASAKI, Amy Zhou, Stephen T. Oh	2024	1
3	Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1 Blood ·Fan He, Elena Plaza Mayoral, Tim Kong, Daniel A.C. Fisher, Kim Nam Kyung, 池田泰, Christopher T. Letson, Yanbo Yu, Noelle Champagne, Mary C. Fulbright, 玉置繁憲, Angelo B. A. Laranjeira, 美代子前澤, Katrina Ashworth, Stephen M. Sykes, Jorge Di Paola, Stephen T. Oh	2024	1
4	In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms Blood ·Angelo B. A. Laranjeira, Tim Kong, Rosewitha Irawaty, Mary C. Fulbright, Daniel A.C. Fisher, Daniel T. Starczynowski, Stephen T. Oh	2024	7
5	Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms Experimental Hematology ·飛奈宏幸, Angelo B. A. Laranjeira, Tim Kong, Mary C. Fulbright, Daniel A.C. Fisher, Christopher M. Sturgeon, Luís F.Z. Batista, Stephen T. Oh	2024	1
6	Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis Blood Advances ·Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean‐Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah Buckley, Shanthakumar Tyavanagimatt, Bryan Harder, 刘曜国, Jennifer A. Smith, Adam R. Craig, John Mascarenhas, Srđan Verstovšek	2023	39
7	Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms American Journal of Hematology ·Tim Kong, Pil J. Yoo, Angelo B. A. Laranjeira, Daniel A.C. Fisher, Lebedeva Lyudmila, Tsuneo IWASAKI, Stephen T. Oh	2023	9
8	Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice Experimental Hematology ·Daniel A.C. Fisher, Angelo B. A. Laranjeira, Tim Kong, Rosewitha Irawaty, Kevin G. Shim, Mary C. Fulbright, Stephen T. Oh	2023	1
9	Abstract PR02: RSK1 targeting impedes oncogenic driver and inflammatory cytokine signaling to attenuate myeloid neoplasms Blood Cancer Discovery ·Tim Kong, Angelo B. A. Laranjeira, Stephen T. Oh	2023	1
10	Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms Journal of Clinical Investigation ·Lebedeva Lyudmila, Angelo B. A. Laranjeira, Tim Kong, Elena Plaza Mayoral, Katrina Ashworth, Alice Liu, Nina Lasky, Daniel A.C. Fisher, Tsuneo IWASAKI, Mary C. Fulbright, Галдилов Григорий Дмитриевич, Pil J. Yoo, 池田泰, Bei Gao, Stephen M. Sykes, Angelo D’Alessandro, Jorge Di Paola, Stephen T. Oh	2023	15
11	RSK1 Is an Exploitable Dependency in Myeloid Malignancies Blood ·Tim Kong, Angelo B. A. Laranjeira, Pil J. Yoo, Jared S. Fowles, Daniel A.C. Fisher, Rameez Ahmad, Wei Yang, M. M. ADAK, Tsuneo IWASAKI, Mary C. Fulbright, Stacey Rentschler, M. L. Mingot-Daveran, Gerrit Los, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh	2023	2
12	DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression Nature Cancer ·Tim Kong, Angelo B. A. Laranjeira, Kalyani Tukaram Bhandwalkar, Daniel A.C. Fisher, Pil J. Yoo, Владимир Бабич, Anthony Z. Wang, Marianna B. Ruzinova, Jared S. Fowles, Mary C. Fulbright, Tsuneo IWASAKI, Hamza Celik, Grant A. Challen, Sidong Huang, Stephen T. Oh	2022	25
13	Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies Blood ·Tim Kong, Angelo B. A. Laranjeira, Pil J. Yoo, Jared S. Fowles, Fan He, Bruna de Araujo Silva, Stephen T. Oh	2022	1
14	Comprehensive Profiling of Clinical JAK2 Inhibitors in Myeloproliferative Neoplasms Blood ·Tim Kong, Pil J. Yoo, Angelo B. A. Laranjeira, Fan He, Bruna de Araujo Silva, Stephen T. Oh	2022	2
15	Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Blood Advances ·Tim Kong, Angelo B. A. Laranjeira, 飛奈宏幸, Kathleen H. Groover, Brazil M. Colõ, Mary C. Fulbright, Marianna B. Ruzinova, Hamza Celik, Grant A. Challen, Daniel A.C. Fisher, Stephen T. Oh	2021	12
16	eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer Molecular Cancer Therapeutics ·Tim Kong, Yibo Xue, Regina Cencic, Xianbing Zhu, Anie Monast, Zheng Qing Fu, Mary Courtis, Veena Sangwan, Marie‐Christine Guiot, William D. Foulkes, John A. Porco, Morag Park, Jerry Pelletier, Sidong Huang	2019	33
17	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers Cancer Research ·Tim Kong, Ryuhjin Ahn, Kalyani Tukaram Bhandwalkar, Xianbing Zhu, Zheng Fu, Geneviève Morin, Muhamad Farhan, В. П. Любин, Yibo Xue, Hellen Kuasne, Qinghao Li, Sungmi Jung, Anne V. Gonzalez, Sophie Camilleri‐Broët, Marie‐Christine Guiot, Morag Park, Josie Ursini‐Siegel, Sidong Huang	2019	103
18	Direct Binding between Pre-S1 and TRP-like Domains in TRPP Channels Mediates Gating and Functional Regulation by PIP2 Cell Reports ·Wang Zheng, Ruiqi Cai, Walter Lindley, Vasyl Nesin, 源醫낅뜒, Wentong Long, Mohammad Fatehi, Xiong Liu, Shaimaa Hussein, Tim Kong, Jingru Li, Peter E. Light, Jingfeng Tang, Veit Flockerzi, Leonidas Tsiokas, Xing-Zhen Chen	2018	35
19	Identification and characterization of hydrophobic gate residues in TRP channels The FASEB Journal ·Wang Zheng, G. T. Rizzo, Ruiqi Cai, Walter Lindley, 源醫낅뜒, Mohammad Fatehi, Wentong Long, Tim Kong, Jingfeng Tang, Peter E. Light, Veit Flockerzi, Ying Cao, Xing‐Zhen Chen	2017	29
20	Large-scale circuit placement: gap and promise Jason Cong, Tim Kong, Basri MN, Min Xie, Xin Yuan	2003	5

About Tim Kong

Tim Kong is a scholar working on Genetics, Hematology, Sensory Systems, Hardware and Architecture and Toxicology, having authored 24 papers that have together received 357 indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (12 papers), Kruppel-like factors research (6 papers), Cytokine Signaling Pathways and Interactions (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), VLSI and FPGA Design Techniques (2 papers), Eosinophilic Disorders and Syndromes (2 papers) and VLSI and Analog Circuit Testing (2 papers). The work is most often cited by research in Genetics (93 citations), Sensory Systems (36 citations), Hematology (74 citations), Oncology (94 citations) and Molecular Biology (188 citations). Tim Kong has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Stephen T. Oh, Sidong Huang, Xianbing Zhu, Marie‐Christine Guiot, Yibo Xue, Morag Park, Angelo B. A. Laranjeira, Geneviève Morin, Josie Ursini‐Siegel and Wang Zheng. Their work appears in journals such as Blood, Blood Advances, Experimental Hematology, Molecular Cancer Therapeutics and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact